Entry Point Capital, LLC Day One Biopharmaceuticals, Inc. Call Options Transaction History
Entry Point Capital, LLC
- $221 Million
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DAWN
# of Institutions
176Shares Held
77.8MCall Options Held
139KPut Options Held
253K-
Atlas Venture Life Science Advisors, LLC6.43MShares$55.9 Million13.44% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.85MShares$50.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA5.76MShares$50.1 Million1.18% of portfolio
-
Braidwell LP Stamford, CT4.87MShares$42.4 Million3.46% of portfolio
-
Black Rock Inc. New York, NY4.53MShares$39.4 Million0.0% of portfolio
About Day One Biopharmaceuticals, Inc.
- Ticker DAWN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 73,461,104
- Market Cap $639M
- Description
- Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...